Toripalimab for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study is a real-world experience (not a strict experiment) for people with extensive-stage small cell lung cancer who are about to start treatment with the immunotherapy drug toripalimab. It simply tracks how you do during your regular care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (cancer that has spread widely in your chest or to other parts of the body).
- Your doctor plans to start treatment with toripalimab (an immunotherapy drug) as your first cancer therapy.
- You are willing to sign a consent form and let the study team review your medical records.
- You are not pregnant or breastfeeding.
- You have not had an allergic reaction to toripalimab or similar immunotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug toripalimab with standard chemotherapy for people with advanced small cell lung cancer that has gotten worse after previous treatments. It aims to see if this combination can help control the cancer.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
This trial tests whether a combination of two immunotherapy drugs (toripalimab and JS004) plus chemotherapy can help control relapsed or extensive-stage small cell lung cancer. It is designed for people whose cancer has spread or returned and who are generally healthy enough to receive strong treatment.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This trial tests a combination of two drugs, toripalimab and anlotinib, as maintenance therapy after initial treatment for extensive stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from growing for as long as possible.
Hear when a new Toripalimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.